secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001728117-25-000082
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Bio Q3 net loss $48.2M; PROSERA topline due Feb 2026
-------------------------------------------------------------

- Net loss of $48.2M ($0.21 per share) vs $30.8M loss a year ago; revenue from Chiesi collab $13.3M.
- Cash, cash equivalents and marketable securities $180.2M; sufficient to fund ops into 2027.
- PROSERA Phase 3 PAH study enrollment complete (390 pts); topline results expected February 2026.
- First site activated for SERANATA Phase 3 PH-ILD study; targeting enrollment of ~480 patients.
- Strategic option agreement to acquire Respira via 1.5M shares; no new trials expected before 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811725000082/0001728117-25-000082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811725000082/goss-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001728117-25-000082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer